Manzoor khan
@mzk1987.bsky.social
Hemato-oncologist ,internist,politically free
BMT Fellow QEHB,UK
Special interest IN MM/Lymphoma/BMT
BMT Fellow QEHB,UK
Special interest IN MM/Lymphoma/BMT
Reposted by Manzoor khan
Ibru+ven x 16➡️ibru+obinu x 6 if MRD+ (if uMRD-, obs) #ASH24:
- 84 pts, 7% TP53mut, 57% very high CLL-IPI
- 21% uMRD➡️obs: 2-yr PFS 94%
- 79% MRD+➡️IO intensification: 60% achieved subsequent uMRD, 2-yr PFS 92%
60% of all pts achieved uMRD. Time-limited tx strategies ftw! #leusm
- 84 pts, 7% TP53mut, 57% very high CLL-IPI
- 21% uMRD➡️obs: 2-yr PFS 94%
- 79% MRD+➡️IO intensification: 60% achieved subsequent uMRD, 2-yr PFS 92%
60% of all pts achieved uMRD. Time-limited tx strategies ftw! #leusm
November 27, 2024 at 5:40 AM
Reposted by Manzoor khan
#ASH24 Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd)
-CTC is an independent prognostic factor
-HR cytogenetics + CTC => dismal outcome
#mmsm #bmtsm ash.confex.com/ash/2024/web...
-CTC is an independent prognostic factor
-HR cytogenetics + CTC => dismal outcome
#mmsm #bmtsm ash.confex.com/ash/2024/web...
Paper: Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Indu...
ash.confex.com
November 22, 2024 at 4:16 AM
#ASH24 Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd)
-CTC is an independent prognostic factor
-HR cytogenetics + CTC => dismal outcome
#mmsm #bmtsm ash.confex.com/ash/2024/web...
-CTC is an independent prognostic factor
-HR cytogenetics + CTC => dismal outcome
#mmsm #bmtsm ash.confex.com/ash/2024/web...
Reposted by Manzoor khan
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
ascopubs.org
November 19, 2024 at 2:20 AM
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
@szusmani.bsky.social
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
November 18, 2024 at 6:56 PM
@szusmani.bsky.social
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
Updated breast cancer algorthim with updated data....
November 18, 2024 at 7:31 AM
Updated breast cancer algorthim with updated data....
@medihumdani.bsky.social
Great Talk by Dr.Mehdi Hamdini bhai at PCUH (PSH)
.Very informative talk.
Can we have the whole ppt?
Great Talk by Dr.Mehdi Hamdini bhai at PCUH (PSH)
.Very informative talk.
Can we have the whole ppt?
November 17, 2024 at 10:29 PM
@medihumdani.bsky.social
Great Talk by Dr.Mehdi Hamdini bhai at PCUH (PSH)
.Very informative talk.
Can we have the whole ppt?
Great Talk by Dr.Mehdi Hamdini bhai at PCUH (PSH)
.Very informative talk.
Can we have the whole ppt?
Nice algorithmic approach
November 17, 2024 at 10:09 PM
Nice algorithmic approach
Looks much similar to X.
Hopefully, it will be a great experience with skyblue.
Nice transition from X to sky blue.
Hopefully, it will be a great experience with skyblue.
Nice transition from X to sky blue.
November 17, 2024 at 10:04 PM
Looks much similar to X.
Hopefully, it will be a great experience with skyblue.
Nice transition from X to sky blue.
Hopefully, it will be a great experience with skyblue.
Nice transition from X to sky blue.